固态肿瘤靶向蛋白市场：依适应症、标靶类别、治疗方法和作用机制划分－2026-2032年全球预测

预计到 2025 年，固态肿瘤靶向蛋白市场价值将达到 16.2 亿美元，到 2026 年将成长至 17.8 亿美元，到 2032 年将达到 31.8 亿美元，年复合成长率为 10.08%。

关键市场统计数据
基准年 2025	16.2亿美元
预计年份：2026年	17.8亿美元
预测年份 2032	31.8亿美元
复合年增长率 (%)	10.08%

本文从战略角度概述了正在重塑靶向蛋白在癌症治疗中开发和临床应用的科学、监管和商业趋势的融合。

固态肿瘤标靶蛋白的治疗模式正处于一个转折点，科学创新、临床紧迫性和商业性规范在此交汇，重新定义了肿瘤学的可能性。分子生物学、精准诊断和免疫调节的进步正在拓展可靶向靶点的选择范围，并迫使跨学科团队重新思考标靶检验、试验设计和价值实现。同时，监管机构和支付方对证据标准和真实世界治疗结果提出了新的要求，这些要求在关键结果获得之前就已影响研发决策。本导言将读者置于这些动态的交会点，并简明扼要地阐述了指导药物发现、开发和商业化策略选择的关键趋势。

综合审视重大科学突破、监管变革和资本配置调整，这些因素正在重新定义标靶肿瘤治疗计画的策略重点。

固态肿瘤靶向蛋白领域正经历着一场变革性的转变，其驱动力来自科学突破、监管政策的演变以及资金配置的调整。在科学层面，单细胞定序、空间生物学和系统免疫学以前所未有的分辨率绘製了肿瘤异质性及其与微环境的相互作用图谱。这些进展使得标靶选择更加精准，并能设计出兼顾肿瘤内在抗药性机制和免疫介导抗药性机制的联合治疗策略。因此，传统上依赖单一标靶单药疗法的治疗方案正转向多模态治疗方法和适应性研发路径。

对2025年美国关税环境可能如何重塑癌症治疗药物开发商的供应链、监管合作和商业化准备全面评估

美国将于2025年生效的新关税，除了直接的成本压力外，还将为肿瘤治疗药物研发企业带来一系列营运和策略方面的考量。生物製药、抗体药物复合体和关键试剂的供应链遍布全球，通常涉及多个跨境流程，包括原料采购、契约製造和分销。因此，关税调整可能会改变企业在近岸外包、双重采购和库存管理方面的奖励。为此，各企业需要重新评估其供应商布局，优先考虑生产的柔软性，并加快二级供应商的合格，以避免下游临床试验和产品上市受到干扰。

简洁、可操作的细分讯息，整合了适应症亚型、治疗方式、标靶类别和作用机制，以优化研发优先排序和试验设计。

了解市场区隔对于资源优先分配、使科学研究工作与临床需求和商业性机会保持一致至关重要。根据适应症，市场涵盖乳癌、大肠癌、肺癌、卵巢和摄护腺癌。乳癌进一步细分为HER2阳性、荷尔蒙受体阳性和三阴性亚型，而肺癌则细分为非小细胞肺癌和小细胞肺癌。这种细分有助于明确亚型特异性生物学和未满足的需求如何指导标靶检验和试验族群选择。将治疗假设与这些适应症和亚型相匹配，有助于研发人员调整註册策略和生物标记开发，从而提高讯号检测能力和监管审核准备。

区域比较分析：美洲、欧洲、中东和非洲以及亚太地区肿瘤计画的临床试验能力、监管差异和商业化考量

区域趋势对临床开发、监管策略和商业化路径有显着影响。在美洲，完善的临床试验基础设施和成熟的报销体系为后期研究和早期商业化创造了有利环境。然而，研发者必须应对价格压力和支付方对疗效证据的要求，这些要求强调疗效的比较。儘管某些适应症的区域生态系统支持快速招募患者，但申办者仍应制定能够预见不同支付方期望的准入策略，并酌情纳入真实世界数据和基本契约。

竞争格局概述，重点介绍领先的製药和创新生物技术公司的产品组合策略、合作活动和能力重点。

肿瘤领域的竞争格局呈现出大型製药企业、灵活敏捷的生物技术公司和专业平台开发商并存的局面，它们都在竞相将生物目标转化为可持续的患者获益。成熟的肿瘤领域领导企业不断利用其规模优势、整合的研发能力和全球商业化网络，加速后期专案的进展并拓展至更广泛的适应症。同时，新兴生物技术公司透过专注的标靶发现、新型疗法以及快速的、假设驱动的临床开发来推动创新，并常常与大型公司建立策略合作伙伴关係和达成许可协议。

一系列具有重大影响的营运和策略优先建议，旨在加速临床转化、增强供应链韧性并明确肿瘤学领域的商业性差异化。

行业领导者必须采取果断行动，将科学潜力转化为持续的患者获益和商业性成功。首先，他们应优先考虑具有强大转化桥樑的项目，投资于早期生物标记检验、适应性试验设计以及转化终点，从而提高与监管机构和支付方评估标准明确匹配的可能性。加强转化科学将降低后期试验失败率，并带来更具吸引力的价值提案。其次，他们应透过合格多家契约製造组织 (CMO) 进行资格认证、探索区域生产伙伴关係关係以及在专案里程碑中纳入紧急时应对计画来增强供应链韧性，从而降低关税和物流波动带来的风险。

本文详细概述了用于获取肿瘤标靶蛋白可靠资讯的详细调查方法，包括资料收集方法、分析框架和检验程序。

为确保结论的严谨性和可操作性，本研究采用结构化的分析架构整合了第一手和第二手资讯。第一手资料来源包括对临床研究人员、监管专家和商业领袖的访谈，并辅以对同行评审文献、临床试验註册库和已发布的监管指南的系统性回顾。第二手综合分析则汇集了特定治疗方法的研发模式、转化生物标记证据以及已记录的供应链实践，建构了一个全面且检验的叙述，对从研发到商业化的决策者都具有参考价值。

简明扼要的结论，整合了科学趋势、监管发展和实际需要，旨在指导肿瘤学相关人员的决策。

总之，不断演变的肿瘤生物学、日益成熟的标靶治疗和免疫疗法，以及全球研发领域不断变化的营运现实，共同定义了肿瘤创新发展的下一阶段。能够将严谨的转化证据与灵活的研发模式和稳健的供应链结合的机构将取得成功。监管环境和支付方越来越重视清晰的价值提案和可靠的真实世界证据计划，这意味着临床成功必须与从专案设计初期就采取的积极准入策略紧密相连。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章固态肿瘤靶向蛋白市场（依适应症划分）

• 乳癌
  • HER2阳性
  • 荷尔蒙受体阳性
  • 三重否定
• 大肠直肠癌
• 肺癌
  • 非小细胞肺癌
  • 小细胞肺癌
• 卵巢癌
• 摄护腺癌

第九章固态肿瘤靶向蛋白市场依标靶分类

• 查核点抑制剂
  • CTLA-4
  • PD-1
  • PD-L1
• DNA修復蛋白
• 生长因子受体
  • EGFR
  • HER2
  • VEGFR
• 激酶抑制剂
  • 丝胺酸/苏胺酸激酶抑制剂
  • 蛋白酪氨酸激酶抑制剂
• 核受体

第十章固态肿瘤靶向蛋白市场（治疗方法）

• 抗体药物复合体
• CAR-T
• 单株抗体
  • 嵌合体体
  • 完全人类
  • 人性化
• 低分子化合物

第十一章固态肿瘤靶向蛋白市场（依作用机制划分）

• 变构抑制剂
• DNA损伤剂
• 荷尔蒙受体拮抗剂
• 免疫查核点抑制剂
• 受体蛋白酪氨酸激酶抑制剂

第十二章固态肿瘤靶向蛋白市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章固态肿瘤靶向蛋白市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国固态肿瘤标靶蛋白市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

15. 美国固态肿瘤靶向蛋白市场

16. 中国固态肿瘤靶向蛋白市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Genentech, Inc.
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi
• Takeda Pharmaceutical Company Limited

The Solid Tumors Target Proteins Market was valued at USD 1.62 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 10.08%, reaching USD 3.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.62 billion
Estimated Year [2026]	USD 1.78 billion
Forecast Year [2032]	USD 3.18 billion
CAGR (%)	10.08%

A strategic orientation summarizing the converging scientific, regulatory, and commercial dynamics reshaping target protein development and clinical translation in oncology

The therapeutic landscape for solid tumor target proteins is at a pivotal juncture where scientific innovation, clinical urgency, and commercial discipline converge to redefine what is possible in oncology. Advances in molecular biology, precision diagnostics, and immune modulation have expanded the menu of actionable targets, prompting cross-disciplinary teams to rethink target validation, trial design, and value capture. Concurrently, regulatory agencies and payers are signaling new expectations around evidentiary standards and real-world outcomes, which influences go/no-go decisions long before pivotal readouts. This introduction situates readers at the intersection of these forces, providing a concise orientation to the major trends that inform strategic choices across discovery, development, and commercialization.

Through an integrated lens that spans biology, translational strategy, and market execution, this section foregrounds the primary vectors of change: deeper mechanistic understanding of tumor biology, the maturation of targeted and immune-based modalities, and the operational complexities of global development. The narrative that follows is structured to help senior leaders, clinical program directors, and commercial strategists quickly synthesize the implications of these dynamics and to identify where focused investment and disciplined stage-gating will yield the greatest returns. By emphasizing pragmatic translation and risk-managed innovation, this introduction prepares readers to evaluate subsequent sections with a clear sense of priority and context.

A synthesis of the major scientific breakthroughs regulatory changes and capital allocation shifts that are redefining strategic priorities in oncology target programs

The landscape for solid tumor target proteins has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and shifting capital allocation. At the scientific level, single-cell sequencing, spatial biology, and systems immunology have made it possible to map tumor heterogeneity and microenvironment interactions with unprecedented resolution. These advances enable finer-grained target selection and the design of combination strategies that account for both tumor-intrinsic and immune-mediated resistance mechanisms. As a result, programs that previously relied on single-target monotherapies are now pivoting toward multimodal regimens and adaptive development pathways.

Regulatory frameworks and payer expectations have become more sophisticated, rewarding programs that integrate biomarkers, companion diagnostics, and robust real-world evidence collection from the outset. This evolution accelerates approval pathways for agents that demonstrate clear patient-centered benefit, while raising the bar for long-term value demonstration. Investment patterns have also shifted: venture and corporate capital increasingly favor de-risked assets, platform technologies with broad applicability, and strategic alliances that can compress timelines and broaden market access. In combination, these forces are reshaping prioritization, encouraging cross-sector collaboration, and elevating translational rigor as the principal determinant of long-term success.

A comprehensive assessment of how the 2025 United States tariff environment may reshape supply chains regulatory collaborations and commercial readiness for oncology developers

The adoption of new tariff measures in the United States in 2025 introduces a set of operational and strategic considerations for oncology developers that extend beyond immediate cost pressures. Supply chains for biologics, antibody-drug conjugates, and critical reagents are global and often involve multiple cross-border steps including material sourcing, contract manufacturing, and distribution. Tariff adjustments can therefore alter incentives for nearshoring, dual-sourcing, and inventory management. In response, organizations must reassess supplier footprints, prioritize manufacturing flexibility, and accelerate qualification of secondary suppliers to avoid downstream trial and launch interruptions.

Beyond logistics, tariff-induced shifts can influence collaborative models and licensing negotiations. Partners and licensors will recalibrate risk-sharing frameworks to account for altered landed costs and timing uncertainty. Research collaborations that involve cross-border reagent transfers or multi-site manufacturing may require contractual amendments to reflect changing duties and customs regimes. Importantly, program leaders must differentiate short-term operational responses from longer-term strategic changes; while some adjustments are tactical, others create an inflection point to restructure supply networks, expand regional manufacturing capacity, and revisit channel economics for commercial launches. In short, tariffs in 2025 serve as a catalyst for greater supply resilience, more explicit contingency planning, and deeper alignment between commercial and manufacturing strategy.

Concise and actionable segmentation intelligence integrating indication subtype therapeutic modality target class and mechanism of action to optimize development prioritization and trial design

Understanding segmentation is essential to prioritize resources and to align scientific efforts with clinical need and commercial opportunity. Based on indication, the market is studied across breast cancer, colorectal cancer, lung cancer, ovarian cancer, and prostate cancer, with breast cancer examined further across HER2 positive, hormone receptor positive, and triple-negative subtypes, and lung cancer parsed into non-small cell lung cancer and small cell lung cancer; this granularity clarifies how subtype-specific biology and unmet need should guide target validation and trial population selection. By mapping therapeutic hypotheses to these indications and subtypes, developers can align enrollment strategies and biomarker development to improve signal detection and regulatory readiness.

Based on target class, programs are categorized across checkpoint inhibitors, DNA repair proteins, growth factor receptors, kinase inhibitors, and nuclear receptors, with checkpoint inhibitors explored across CTLA-4, PD-1, and PD-L1, growth factor receptors delineated into EGFR, HER2, and VEGFR, and kinase inhibitors further classified into serine/threonine and tyrosine kinase inhibitors; this classification helps R&D teams prioritize modality fit and combination hypotheses that address resistance biology. Based on therapeutic modality, research spans antibody-drug conjugates, CAR T, monoclonal antibodies, and small molecules, while monoclonal antibodies are differentiated into chimeric, fully human, and humanized constructs; this view supports decisions about manufacturing complexity, clinical development timelines, and differentiation strategies. Finally, based on mechanism of action, focus areas include allosteric inhibitors, DNA damage agents, hormone receptor antagonists, immune checkpoint blockers, and receptor tyrosine kinase inhibitors; coupling mechanism-level insights with indication and modality considerations yields a precise lens for portfolio rationalization and translational planning.

Comparative regional intelligence highlighting clinical trial capacity regulatory divergence and commercialization considerations across Americas EMEA and Asia Pacific for oncology programs

Regional dynamics exert a profound influence on clinical development, regulatory strategy, and commercialization pathways. In the Americas, robust clinical trial infrastructure and established reimbursement frameworks create a favorable environment for late-stage studies and early commercial rollout, yet developers must navigate pricing pressures and payer evidence requirements that emphasize comparative effectiveness. The regional ecosystem supports rapid enrollment for certain indications, but sponsors should plan for diverse payer expectations and develop access strategies that incorporate real-world evidence and outcomes-based contracting where appropriate.

In Europe, Middle East & Africa, regulatory heterogeneity and variable health system maturity require tailored market access approaches that balance centralized regulatory pathways with country-specific launch sequencing. Sponsors must calibrate value dossiers to local health economics expectations and design post-approval evidence generation programs that align with national payer priorities. The Asia-Pacific region presents a mix of high-capacity clinical sites, fast-growing biotech hubs, and divergent regulatory timelines; this creates opportunities to accelerate enrollment and regionally adapt development strategies, while also requiring attention to local manufacturing requirements, regulatory dossier localization, and culturally informed patient engagement. Across regions, strategic use of regulatory science, early payer dialogue, and adaptive commercialization planning will determine how rapidly and effectively therapies transition from trial success to patient impact.

High-level competitive landscape observations emphasizing portfolio strategy alliance activity and capability priorities among leading pharmaceutical companies and innovative biotechs

The competitive landscape in oncology is characterized by a mix of large pharmaceutical companies, nimble biotechs, and specialized platform developers, all competing to translate target biology into durable patient benefit. Established oncology leaders continue to leverage scale, integrated R&D capabilities, and global commercialization networks to accelerate late-stage programs and to execute broad label expansions. At the same time, emerging biotech firms drive innovation through focused target discovery, novel modalities, and rapid, hypothesis-driven clinical development that often culminates in strategic partnerships or licensing deals with larger collaborators.

Corporate strategy in this space increasingly emphasizes alliance activity, platform investments, and the pursuit of differentiated clinical niches rather than broad, undifferentiated indications. Companies that combine disciplined biomarker strategies with manufacturing agility and payer-aligned evidence generation gain a competitive edge. Portfolio managers are prioritizing assets with clear pathways to differentiation, durable responses, and manageable manufacturing profiles. For stakeholders, the primary implication is that competitive positioning hinges on an integrated capability set that spans translational science, clinical operations, regulatory strategy, and commercial access planning rather than on single-dimensional scientific novelty alone.

A prioritized set of high-impact operational and strategic recommendations to accelerate clinical translation enhance supply resilience and sharpen commercial differentiation in oncology

Industry leaders must act decisively to convert scientific promise into sustained patient impact and commercial success. First, prioritize programs with robust translational bridges by investing in early biomarker validation, adaptive trial designs, and translational endpoints that increase the probability of clear regulatory and payer-readout alignment. Strengthening translational science reduces late-stage attrition and enables more persuasive value narratives. Second, build supply resilience by qualifying multiple contract manufacturing organizations, exploring regional manufacturing partnerships, and embedding contingency planning into program milestones to mitigate tariff and logistics volatility.

Third, pursue pragmatic combination strategies that are biologically justified and operationally feasible, aligning trial designs with endpoints that matter to regulators and payers. Fourth, engage payers and health technology assessment bodies early to co-design evidence generation plans that address reimbursement criteria and to explore innovative contracting models that share risk and reward. Finally, foster strategic alliances that complement internal capabilities, whether through platform licensing, co-development agreements, or targeted acquisitions that accelerate access to complementary modalities and regional channels. Taken together, these recommendations create a cohesive roadmap for translating molecular insight into durable patient outcomes and commercial viability.

A detailed methodology summary explaining data collection approaches analytical frameworks and validation steps used to produce reliable insights on oncology target proteins

This research synthesizes primary and secondary inputs using structured analytical frameworks to ensure that conclusions are both rigorous and actionable. Primary data sources include expert interviews with clinical investigators, regulatory specialists, and commercial leaders, supported by systematic reviews of peer-reviewed literature, clinical trial registries, and public regulatory guidance. Secondary synthesis integrates modality-specific development patterns, translational biomarker evidence, and documented supply chain practices to construct holistically validated narratives that are relevant to decision-makers across R&D and commercial functions.

Analytical methods include cross-sectional mapping of indication-to-mechanism linkages, scenario analysis to stress-test supply chain and tariff impacts, and portfolio-level trade-off modeling to prioritize assets based on translational de-risking criteria rather than numeric market forecasts. Validation steps involve triangulating interview findings with documented trial outcomes and regulatory precedents, and conducting sensitivity checks to ensure that recommended actions hold up under plausible operational and policy shifts. The methodology emphasizes transparency, reproducibility, and direct applicability so that stakeholders can adapt the approach to their internal decision-making processes.

A concise integrative conclusion synthesizing scientific trends regulatory momentum and practical imperatives to guide decision-making for oncology stakeholders

In conclusion, the evolving science of tumor biology, the maturation of targeted and immune-based modalities, and the changing operational realities of global development collectively define the next phase of oncology innovation. Success will favor organizations that marry rigorous translational evidence with flexible development models and resilient supply chains. Regulatory and payer landscapes increasingly reward clearly articulated value propositions and robust real-world evidence plans, which means that clinical success must be paired with proactive access strategies from early stages of program design.

Moving forward, stakeholders should prioritize programs with strong mechanistic rationales, invest early in biomarker and diagnostic alignment, and design development pathways that anticipate regional regulatory and commercial nuances. By doing so, developers can maximize the likelihood that promising scientific discoveries translate into meaningful improvements in patient outcomes and sustainable business models. The integrated insights presented here offer a pragmatic compass for aligning scientific ambition with operational discipline and commercial realities.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solid Tumors Target Proteins Market, by Indication

• 8.1. Breast Cancer
  • 8.1.1. Her2 Positive
  • 8.1.2. Hormone Receptor Positive
  • 8.1.3. Triple Negative
• 8.2. Colorectal Cancer
• 8.3. Lung Cancer
  • 8.3.1. Non-Small Cell Lung Cancer
  • 8.3.2. Small Cell Lung Cancer
• 8.4. Ovarian Cancer
• 8.5. Prostate Cancer

9. Solid Tumors Target Proteins Market, by Target Class

• 9.1. Checkpoint Inhibitors
  • 9.1.1. Ctla-4
  • 9.1.2. Pd-1
  • 9.1.3. Pd-L1
• 9.2. Dna Repair Proteins
• 9.3. Growth Factor Receptors
  • 9.3.1. Egfr
  • 9.3.2. Her2
  • 9.3.3. Vegfr
• 9.4. Kinase Inhibitors
  • 9.4.1. Serine Threonine Kinase Inhibitors
  • 9.4.2. Tyrosine Kinase Inhibitors
• 9.5. Nuclear Receptors

10. Solid Tumors Target Proteins Market, by Therapeutic Modality

• 10.1. Antibody Drug Conjugates
• 10.2. Car T
• 10.3. Monoclonal Antibodies
  • 10.3.1. Chimeric
  • 10.3.2. Fully Human
  • 10.3.3. Humanized
• 10.4. Small Molecules

11. Solid Tumors Target Proteins Market, by Mechanism Of Action

• 11.1. Allosteric Inhibitors
• 11.2. Dna Damage Agents
• 11.3. Hormone Receptor Antagonists
• 11.4. Immune Checkpoint Blockers
• 11.5. Receptor Tyrosine Kinase Inhibitors

12. Solid Tumors Target Proteins Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Solid Tumors Target Proteins Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Solid Tumors Target Proteins Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Solid Tumors Target Proteins Market

16. China Solid Tumors Target Proteins Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. AbbVie Inc.
• 17.6. Amgen Inc.
• 17.7. AstraZeneca PLC
• 17.8. Bayer AG
• 17.9. Boehringer Ingelheim International GmbH
• 17.10. Bristol-Myers Squibb Company
• 17.11. Celgene Corporation
• 17.12. Daiichi Sankyo Company, Limited
• 17.13. Eli Lilly and Company
• 17.14. Genentech, Inc.
• 17.15. GlaxoSmithKline plc
• 17.16. Janssen Pharmaceuticals, Inc.
• 17.17. Johnson & Johnson
• 17.18. Merck & Co., Inc.
• 17.19. Novartis AG
• 17.20. Pfizer Inc.
• 17.21. Regeneron Pharmaceuticals, Inc.
• 17.22. Roche Holding AG
• 17.23. Sanofi
• 17.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 118. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 119. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 120. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 121. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 122. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 123. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 124. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 125. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 126. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 127. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 128. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 131. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 132. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 133. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 134. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 136. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 137. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 138. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 139. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 140. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 141. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 142. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 144. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 145. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 146. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 147. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 148. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 150. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 162. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 163. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 164. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 165. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 166. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 167. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 168. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 169. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 170. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 171. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 172. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 173. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 174. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 175. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 176. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 177. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 178. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 179. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 180. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 181. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 182. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 183. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 184. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 185. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 186. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 187. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 188. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 189. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 190. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 191. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 192. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 193. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 194. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 195. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 196. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 197. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 198. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 199. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 200. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 201. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 202. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 203. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 204. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 205. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 206. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 207. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 208. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 209. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 210. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 211. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 212. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 213. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 214. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 215. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 216. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 217. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 218. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 219. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 220. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 221. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 222. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 223. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 224. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 225. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 226. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 227. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 228. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 229. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 230. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 231. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 232. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 233. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 234. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 235. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 236. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 237. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 238. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 239. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 240. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 241. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 242. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 243. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 244. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 245. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 246. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 247. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 248. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 249. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 250. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 251. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 252. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 253. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 254. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 255. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 256. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 257. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 258. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 259. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 260. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 261. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 262. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 263. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 264. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 265. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 266. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 267. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 268. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 269. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 270. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 271. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 272. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 273. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 274. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 275. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 276. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 277. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 278. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 279. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 280. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 281. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 282. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 283. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 284. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 285. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 286. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 287. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
• TABLE 288. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
• TABLE 289. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
• TABLE 290. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 291. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
• TABLE 292. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
• TABLE 293. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
• TABLE 294. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
• TABLE 295. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)